# Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

> **NCT05148845** · PHASE3 · UNKNOWN · sponsor: **Wits Health Consortium (Pty) Ltd** · enrollment: 500000 (estimated)

## Conditions studied

- SARS CoV 2 Infection

## Interventions

- **BIOLOGICAL:** Booster vaccine

## Key facts

- **NCT ID:** NCT05148845
- **Lead sponsor:** Wits Health Consortium (Pty) Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-10
- **Primary completion:** 2022-01-31
- **Final completion:** 2023-06
- **Target enrollment:** 500000 (ESTIMATED)
- **Last updated:** 2022-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148845, "Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05148845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*